Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo

被引：19
|
作者：
Soderquist, R. [1 ,2 ]
Bates, D. J. P. [1 ,2 ]
Danilov, A. V. [2 ,3 ]
Eastman, A. [1 ,2 ]
机构：
[1] Giesel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Lebanon, NH USA
[2] Giesel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH USA
[3] Giesel Sch Med Dartmouth, Dept Med, Lebanon, NH USA
来源：
LEUKEMIA | 2013年 / 27卷 / 11期
关键词：
NAVITOCLAX; EXPRESSION; APOPTOSIS; PROTEINS; ABT-263; POTENT;
D O I：
10.1038/leu.2013.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2262 / 2264
页数：4
相关论文
共 50 条
  • [1] Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo
    R Soderquist
    D J P Bates
    A V Danilov
    A Eastman
    Leukemia, 2013, 27 : 2262 - 2264
  • [2] Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
    Moore, Victoria Del Gaizo
    Brown, Jennifer R.
    Certo, Michael
    Love, Tara M.
    Novina, Carl D.
    Letai, Anthony
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01): : 112 - 121
  • [3] Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
    Tromp, Jacqueline M.
    Geest, Christian R.
    Breij, Esther C. W.
    Elias, Judith A.
    van Laar, Jacoline
    Luijks, Dieuwertje M.
    Kater, Arnon P.
    Beaumont, Tim
    van Oers, Marinus H. J.
    Eldering, Eric
    CLINICAL CANCER RESEARCH, 2012, 18 (02) : 487 - 498
  • [4] ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts
    Ugarenko, Michal
    Nudelman, Abraham
    Rephaeli, Ada
    Kimura, Ken-Ichi
    Phillips, Don R.
    Cutts, Suzanne M.
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (03) : 339 - 349
  • [5] Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition
    Davids, Matthew S.
    Letai, Anthony
    Brown, Jennifer R.
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1823 - 1825
  • [6] Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia Response
    Butterworth, Michael
    Vogler, Meike
    Dyer, Martin J. S.
    Cohen, Gerald M.
    BLOOD, 2009, 114 (12) : 2561 - 2562
  • [7] An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
    Al-Harbi, Sayer
    Hill, Brian T.
    Mazumder, Suparna
    Singh, Kamini
    DeVecchio, Jennifer
    Choudhary, Gaurav
    Rybicki, Lisa A.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Houghton, Janet A.
    Almasan, Alexandru
    BLOOD, 2011, 118 (13) : 3579 - 3590
  • [8] ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by overexpression of BCL2 in primary AML blasts.
    Kohl, Tobias M.
    Hellinger, Christine
    Hiddemann, Wolfgang
    Bohlander, Stefan K.
    Spiekermann, Karsten
    BLOOD, 2006, 108 (11) : 158A - 159A
  • [9] Marked sensitivity of chronic lymphocytic leukemia (CLL) to apoptosis induced by BCL2 antagonist ABT-737.
    Vogler, Meike
    Majid, Aneela
    Walewska, Renata
    Dyer, Martin J. S.
    Cohen, Gerald M.
    BLOOD, 2007, 110 (11) : 913A - 913A
  • [10] ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adduct forming treatments in HL-60 cells
    Ugarenko, Michal
    Rephaeli, Ada
    Nudelman, Abraham
    Cutts, Suzi
    Phillips, Don
    CANCER RESEARCH, 2009, 69
12345